Current issue
Archive
About the Journal
About us
Aims and Scope
Indexing and Abstracting
Editorial Office
Open Access Policy
Publication Ethics
Contact
For Authors
Editorial Policy
Peer Review Policy
Manuscript Preparation Guidelines
Copyright & Licensing
Publication Fees
Fast-Track Paper Publication Option
Conflict Interest Guidance
Submit an Article
Special Issues
News & Editorials
“Fake,” “Predatory,” and “Pseudo” Journals: Charlatans Threatening Trust in Science
Shifting the Journal submission-review system to the Editorial System Manuscript December 27, 2017.
ORIGINAL ARTICLE
Role of initial and follow-up IL-6 (Interleukin-6) titre in COVID-19 pneumonia: A single center experience
1
MIMSR Medical College, Latur, INDIA
2
Venkatesh Chest Hospital and Critical Care Center Latur, INDIA
3
Internal Medicine, MIMSR Medical College, Latur, INDIA
4
Department of Pathology, MIMSR Medical College, Latur, INDIA
Publication date: 2022-06-29
Electron J Gen Med 2022;19(5):em390
KEYWORDS
ABSTRACT
Background:
Robust data of IL-6 is available in bacterial infection, and now it can be utilized in currently ongoing COVID-19 (corona virus disease-19) pneumonia pandemic to guide treatment strategy as marker of inflammation.
Methods:
Prospective, observational study included 1,000 COVID-19 cases confirmed with RT PCR (reverse transcription polymerase chain reaction). All cases were undergone categorized after clinical details, HRCT (high resolution computerized tomography) thorax, oxygen saturation, IL-6 (interleukin 6) at entry point and follow up. Age, gender, comorbidity and use BIPAP/NIV (bilevel positive airway pressure/non-invasive ventilation), and outcome as with or without lung fibrosis as per HRCT severity were key observations. Statistical analysis is done by using Chi-square test.
Results:
In study of 1,000 COVID-19 pneumonia cases, age (<50 and >50 years) and gender has significant association with IL-6. HRCT severity score at entry point has significant correlation with IL-6 level (p<0.00001). IL-6 level has significant association with duration of illness (p<0.00001). Comorbidities has significant association with IL-6 level (p<0.00001). IL-6 level has significant association with oxygen saturation (p<0.00001). BIPAP/NIV requirement has significant association with IL-6 level (p<0.00001). Timing of BIPAP/NIV requirement during course of hospitalization has significant association with IL-6 level (p<0.00001). Follow-up IL-6 titer during hospitalization as compared to entry point normal and abnormal IL-6 has significant association with post-COVID-19 lung fibrosis, respectively (p<0.00001).
Conclusion:
IL-6 has very crucial role in COVID-19 pneumonia in predicting severity of illness, progression of illness including ‘cytokine storm’ and assessing response to treatment during hospitalization and follow-up titers in analyzing post-COVID-19 lung fibrosis.
Robust data of IL-6 is available in bacterial infection, and now it can be utilized in currently ongoing COVID-19 (corona virus disease-19) pneumonia pandemic to guide treatment strategy as marker of inflammation.
Methods:
Prospective, observational study included 1,000 COVID-19 cases confirmed with RT PCR (reverse transcription polymerase chain reaction). All cases were undergone categorized after clinical details, HRCT (high resolution computerized tomography) thorax, oxygen saturation, IL-6 (interleukin 6) at entry point and follow up. Age, gender, comorbidity and use BIPAP/NIV (bilevel positive airway pressure/non-invasive ventilation), and outcome as with or without lung fibrosis as per HRCT severity were key observations. Statistical analysis is done by using Chi-square test.
Results:
In study of 1,000 COVID-19 pneumonia cases, age (<50 and >50 years) and gender has significant association with IL-6. HRCT severity score at entry point has significant correlation with IL-6 level (p<0.00001). IL-6 level has significant association with duration of illness (p<0.00001). Comorbidities has significant association with IL-6 level (p<0.00001). IL-6 level has significant association with oxygen saturation (p<0.00001). BIPAP/NIV requirement has significant association with IL-6 level (p<0.00001). Timing of BIPAP/NIV requirement during course of hospitalization has significant association with IL-6 level (p<0.00001). Follow-up IL-6 titer during hospitalization as compared to entry point normal and abnormal IL-6 has significant association with post-COVID-19 lung fibrosis, respectively (p<0.00001).
Conclusion:
IL-6 has very crucial role in COVID-19 pneumonia in predicting severity of illness, progression of illness including ‘cytokine storm’ and assessing response to treatment during hospitalization and follow-up titers in analyzing post-COVID-19 lung fibrosis.
REFERENCES (42)
1.
WHO. Coronavirus disease (COVID-19) weekly epidemiological update and weekly operational update. 2021. Available at: https://www.who.int/emergencie... (Accessed: 24 December 2021).
2.
Lippi G, Plebani M. The critical role of laboratory medicine during coronavirus disease 2019 (COVID-19) and other viral outbreaks. Clin Chem Lab Med. 2020;58(7):1063-9. https://doi.org/10.1515/cclm-2... PMid:32191623.
3.
Bohn MK, Lippi G, Horvath A, et al. Molecular, serological, and biochemical diagnosis and monitoring of COVID-19: IFCC taskforce evaluation of the latest evidence. Clin Chem Lab Med. 2020;58:1037-52. https://doi.org/10.1515/cclm-2... PMid:32459192.
4.
Chen LYC, Hoiland RL, Stukas S, Wellington CL, Sekhon MS. Confronting the controversy: Interleukin-6 and the COVID-19 cytokine storm syndrome. Eur Respir J. 2020;56(4):2003006. https://doi.org/10.1183/139930... PMid:32883678 PMCid:PMC7474149.
5.
Lau CS, Hoo SP, Koh JMJ, Phua SK, Aw TC. Performance of the Roche IL-6 chemiluminescent immunoassay in patients with COVID-like respiratory symptoms. J Virol Methods. 2021;296:114224. https://doi.org/10.1016/j.jvir... PMid:34214571 PMCid:PMC8240448.
6.
Kishimoto T, Ishizaka K. Regulation of antibody response in vitro. VII. Enhancing soluble factors for IgG and IgE antibody response. J Immunol. 1973;111:1194-205.
7.
Choy EH, De Benedetti F, Takeuchi T, Hashizume M, John MR, Kishimoto T. Translating IL-6 biology into effective treatments. Nat Rev Rheumatol. 2020;16(6):335-45. https://doi.org/10.1038/s41584... PMid:32327746 PMCid:PMC7178926.
8.
Hashizume M, Tan SL, Takano J, et al. A humanized anti-IL-6R antibody, as an emerging therapeutic option for rheumatoid arthritis: Molecular and cellular mechanistic insights. Int Rev Immunol. 2015;34(3):265-79. https://doi.org/10.3109/088301... PMid:25099958.
9.
Garbers C, Heink S, Korn T, Rose-John S. Interleukin-6: Designing specific therapeutics for a complex cytokine. Nat Rev Drug Discov. 2018;17(6):395-412. https://doi.org/10.1038/nrd.20... PMid:29725131.
10.
Huang CL, Wang YM, Li XW, Ren LL, Zhao JP, Hu Y. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395:497-506. https://doi.org/10.1016/S0140-....
11.
Leisman DE, Ronner L, Pinotti R, Taylor MD, Sinha P, Calfee CS. Cytokine elevation in severe and critical COVID-19: A rapid systematic review, meta-analysis, and comparison with other inflammatory syndromes. Lancet Respir Med. 2020;8:1233-44. https://doi.org/10.1016/S2213-....
12.
Chen LYC, Hoiland RL, Stukas S, Wellington CL, Sekhon MS. Confronting the controversy: Interleukin-6 and the COVID-19 cytokine storm syndrome. Eur Respir J. 2020;56. https://doi.org/10.1183/139930... PMid:32883678 PMCid:PMC7474149.
13.
US Food and Drug Administration. FDA emergency use authorization elecsys IL-6. 2021. Available at: https://www.fda.gov/media/1385... (Accessed: 27 December 2021).
14.
Zhang J, Hao Y, Ou W, et al. Serum interleukin-6 is an indicator for severity in 901 patients with SARS-CoV-2 infection: A cohort study. J Transl Med. 2020;18:406. https://doi.org/10.1186/s12967... PMid:33121497 PMCid:PMC7594951.
15.
Chen LD, Zhang ZY, Wei XJ, et al. Association between cytokine profiles and lung injury in COVID-19 pneumonia. Respir Res. 2020;21:201. https://doi.org/10.1186/s12931... PMid:32727465 PMCid:PMC7389162.
16.
Gubernatorova EO, Gorshkova EA, Polinova AI, Drutskaya, MS. IL-6: Relevance for immunopathology of SARS-CoV-2. Cytokine Growth Factor Rev. 2020;53:13-24. https://doi.org/10.1016/j.cyto... PMid:32475759 PMCid:PMC7237916.
17.
Santa Cruz A, Mendes-Frias A, Oliveira AI, et al. Interleukin-6 is a biomarker for the development of fatal severe acute respiratory syndrome coronavirus 2 pneumonia. Front Immunol. 2021;12:613422. https://doi.org/10.3389/fimmu.... PMid:33679753 PMCid:PMC7930905.
18.
Iannaccone G, Scacciavillani R, Del Buono MG, et al. Weathering the cytokine storm in COVID-19: Therapeutic implications. Cardio Renal Med. 2020;10:277-87. https://doi.org/10.1159/000509... PMid:32599589 PMCid:PMC7360507.
19.
Han H, Ma Q, Li C, et al. Profiling serum cytokines in COVID-19 patients reveals IL-6 and IL-10 are disease severity predictors. Emerg Microbes Infect. 2020;9:1123-30. https://doi.org/10.1080/222217... PMid:32475230 PMCid:PMC7473317.
20.
Rocio LG, Alberto UR, Paloma T, et al. Interleukin-6-based mortality risk model for hospitalised COVID-19 patients. J Allergy Clin Immunol. 2020;146:799-807. https://doi.org/10.1016/j.jaci... PMid:32710975 PMCid:PMC7375283.
21.
Herold T, Jurinovic V, Arnreich C, et al. Elevated levels of IL-6 and CRP predict the need for mechanical ventilation in COVID-19. J Allergy Clin Immunol. 2020;146:128-36. https://doi.org/10.1016/j.jaci... PMid:32425269 PMCid:PMC7233239.
22.
Yuan J, Zou R, Zeng L, et al. The correlation between viral clearance and biochemical outcomes of 94 COVID-19 infected discharged patients. Inflamm Res. 2020;69:599-606. https://doi.org/10.1007/s00011... PMid:32227274 PMCid:PMC7103893.
23.
Tisoncik JR, Korth MJ, Simmons CP, Farrar J, Martin TR, Katze MG. Into the eye of the cytokine storm. Microbiol Mol Biol Rev. 2012;76(1):16-32. https://doi.org/10.1128/MMBR.0... PMid:22390970 PMCid:PMC3294426.
24.
Sun X, Wang T, Cai D, et al. Cytokine storm intervention in the early stages of COVID-19 pneumonia. Cytokine Growth Factor Rev. 2020;53:38-42. https://doi.org/10.1016/j.cyto... PMid:32360420 PMCid:PMC7182527.
25.
Zeng, Z, Yu, H, Chen, H, et al. Longitudinal changes of inflammatory parameters and their correlation with disease severity and outcomes in patients with COVID-19 from Wuhan, China. Crit Care. 2020;24:1-12. https://doi.org/10.1186/s13054... PMid:32854750 PMCid:PMC7450961.
26.
Guaraldi G, Meschiari M, Cozzi-Lepri A, et al. Tocilizumab in patients with severe COVID-19: A retrospective cohort study. Lancet Rheumatol. 2020;2:e474-84. https://doi.org/10.1016/S2665-....
27.
Atal S, Fatima Z. IL-6 inhibitors in the treatment of serious COVID-19: a promising therapy? Pharmaceut Med. 2020;34:223-31.https://doi.org/10.1007/s40290... PMid:32535732 PMCid:PMC7292936.
28.
Liu F, Li L, Xu M, et al. Prognostic value of interleukin-6, C-reactive protein, and procalcitonin in patients with COVID-19. J Clin Virol. 2020;127:104370. https://doi.org/10.1016/j.jcv.... PMid:32344321 PMCid:PMC7194648.
29.
Chen X, Zhao B, Qu Y, et al. Detectable serum severe acute respiratory syndrome coronavirus 2 viral load (RNAemia) is closely correlated with drastically elevated interleukin 6 level in critically ill patients with coronavirus disease 2019. Clin Infect Dis. 2020;71(8):1937-42. https://doi.org/10.1093/cid/ci... PMid:32301997 PMCid:PMC7184354.
30.
Gao Y, Li T, Han M, et al. Diagnostic utility of clinical laboratory data determinations for patients with the severe COVID-19. J Med Virol. 2020;92(7):791-6. https://doi.org/10.1002/jmv.25... PMid:32181911 PMCid:PMC7228247.
31.
Huang KJ, Su IJ, Theron M, et al. An interferon-gamma-related cytokine storm in SARS patients. J Med Virol. 2005;75(2):185-94. https://doi.org/10.1002/jmv.20... PMid:15602737 PMCid:PMC7166886.
32.
Channappanavar R, Perlman S. Pathogenic human coronavirus infections: Causes and consequences of cytokine storm and immunopathology. Semin Immunopathol. 2017;39(5):529-39. https://doi.org/10.1007/s00281... PMid:28466096 PMCid:PMC7079893.
33.
Kim ES, Choe PG, Park WB, et al. Clinical progression and cytokine profiles of Middle East respiratory syndrome coronavirus infection. J Korean Med Sci. 2016;31(11):1717-25. https://doi.org/10.3346/jkms.2... PMid:27709848 PMCid:PMC5056202.
34.
Wong CK, Lam CW, Wu AK, et al. Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome. Clin Exp Immunol. 2004;136(1):95-103. https://doi.org/10.1111/j.1365... PMid:15030519 PMCid:PMC1808997.
35.
Hou H, Zhang B, Huang H, et al. Using IL-2R/lymphocytes for predicting the clinical progression of patients with COVID-19. Clin Exp Immunol. 2020;201(1):76-84. https://doi.org/10.1111/cei.13... PMid:32365221 PMCid:PMC7267633.
36.
Bhandari S, Rankawat G, Singh A, Wadhwani D, Patel B. Evaluation of interleukin-6 and its association with the severity of disease in COVID-19 patients. Indian J Med Spec. 2020;11:132-6. https://doi.org/10.4103/INJMS.....
37.
Aykal G, Esen, H, Seyman, D, Caliskan T. Could IL-6 predict the clinical severity of COVID-19? Turkish J Biochem. 2021;46(5):499-507. https://doi.org/10.1515/tjb-20....
38.
Aziz M, Fatima R, Assaly R. Elevated interleukin-6 and severe COVID-19: A meta-analysis. J Med Virol. 2020;92(11):2283-5. https://doi.org/10.1002/jmv.25... PMid:32343429 PMCid:PMC7267383.
39.
Grifoni E, Valoriani A, Cei F, et al. Interleukin-6 as prognosticator in patients with COVID-19. J Infect. 2020;81:452-82. https://doi.org/10.1016/j.jinf... PMid:32526326 PMCid:PMC7278637.
40.
Xu X, Han M, Li T, et al. Effective treatment of severe COVID-19 patients with tocilizumab. Proc Natl Acad Sci. 2020;;117(20):10970-5. https://doi.org/10.1073/pnas.2... PMid:32350134 PMCid:PMC7245089.
41.
Conrozier T, Lohse A, Balblanc J-C, et al. Biomarker variation in patients successfully treated with tocilizumab for severe coronavirus disease 2019 (COVID-19): Results of a multidisciplinary collaboration. Clin Exp Rheumatol. 2020;38(4):742-7.
42.
Montesarchio V, Parrela R, Iommelli C, et al. Outcomes and biomarker analyses among patients with COVID-19 treated with interleukin 6 (IL-6) receptor antagonist sarilumab at a single institution in Italy. J Immunother Cancer. 2020;8(2):e001089. https://doi.org/10.1136/jitc-2... PMid:32784217 PMCid:PMC7418768.
Share
RELATED ARTICLE
| eISSN: | 2516-3507 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
